期刊文献+

沙立度胺对多发性骨髓瘤患者细胞因子影响的临床研究 被引量:3

Clinical study of effects of thalidomide on cytokines in patients with multiple myeloma
暂未订购
导出
摘要 目的:探讨沙立度胺对多发性骨髓瘤(MM)患者几种细胞因子的免疫调节作用。方法:用ELISA方法检测沙立度胺治疗前后患者血清中干扰素-γ(IFN-γ)、白细胞介素(IL)-6、IL-10浓度的变化。结果:22例患者治疗前IFN-γ水平明显低于正常人(P<0.01),IL-6、IL-10水平明显高于正常人(均P<0.01);治疗后IFN-γ水平较治疗前无明显变化(P>0.05),12例治疗有效者的IL-6、IL-10水平较治疗前明显降低(P<0.01),10例治疗无效者的IL-6、IL-10水平较治疗前降低,但差异无统计学意义(P>0.05)。结论:通过降低MM患者血清中IL-6、IL-10水平可能是沙立度胺治疗MM有效的机制之一。 Objective:To explore the immunoregulatory effects of thalidomide on several cytokines in patients with multiple myeloma(MM). Method:ELISA was used to detect the concentrations of IFN-γ. IL-6、 IL-10 in serum of the MM patients before and after treatment. Result: Compared with the healthy volunteers, serum IFN-γ level decreased significantly ( P〈0.01), and serum IL-6 and IL-10 levels increased significantly( P 〈0.01) in twenty-two MM patients before treatment. Compared with before treatment, the changes of serum IFN-γ level was not significant after thalidomide treatment ( P〉0.05). The serum concentrations of IL-6 and IL-10 in 12 patients of response decreased significantly( P〈0.01), but there was no significant decreases in ten patients of no response ( P〉0. 05). Conclusion:Down-regulating IL-6, IL-10 in serum of MM patients was probably one of the mechanisms of action of thalidomide.
出处 《临床血液学杂志》 CAS 2007年第5期272-274,共3页 Journal of Clinical Hematology
关键词 多发性骨髓瘤 沙立度胺 免疫调节 细胞因子 Multiple myeloma Thalidomide Immunoregulatory Cytokine
  • 相关文献

参考文献15

  • 1SINGHAL S, MEHTA J, DESIKAN R,et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med, 1999,341:1565-1571.
  • 2KLEIN B, TARTE K, JOURDAN M ,et al. Survival and proliferation factors of normal and malignant plasma ceils[J]. Int J Hematol,2003 ,78:106-113.
  • 3王京华,张剑.多发性骨髓瘤患者白细胞介素-6及其受体变化研究[J].临床血液学杂志,2004,17(6):350-351. 被引量:3
  • 4ATSUSHI O, DHARMINDER C, GERRARD T, et al. IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade [J]. J Immunol, 1997,159:2212-2221.
  • 5GADO K, DOMJAN G, HEGYESI H,et al. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma [J]. Cell Biol Int, 2000,24 : 195-209.
  • 6HSIAO Y W, LIAO K W, HUNG S W,et al.Tumorinfiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity [J]. J Immunol, 2004, 172:1508-1514.
  • 7DMOSZYNSKA A, BOJARSKA-JUNAK A, DOMA NSKI D,et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma [J]. Leuk Lymphoma, 2002 ,43:401-406.
  • 8罗绍凯,李娟,洪文德,周振海,邹外一.沙利度胺对骨髓瘤患者免疫学的影响[J].中国新药杂志,2001,10(9):683-685. 被引量:5
  • 9NEBEN K, MOEHLER T, KRAEMER A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion [J]. Br J Haematol, 2001 ,115:605-608.
  • 10THOMPSON M A, WITZIG T E, KUMAR S,et al. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma[J]. Br J Haematol, 2003 , 123:305-308

二级参考文献11

  • 1王学文,杨天楹.难治性和复发性骨髓瘤的治疗进展[J].国外医学(输血及血液学分册),1993,16(1):35-37. 被引量:11
  • 2[1]Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341(12)∶1565-1571.
  • 3[2]GoldmacherVS,Lizabeth A,Bourret BA,et al.Anti-CD38-blocked ricin:an immunotoxin for the treatment of multiple myeloma[J].Blood,1994,84(9)∶3017-3025.
  • 4[3]Kneller A,Raanani P,Hardan I,et al.Therapy with thalidomide in refractory multiple myeloma patients--the revival of an old drug[J].Br J Haematol,2000,108(2)∶391-392.
  • 5[4]Bataille R,Barlogie B,Zhou YL,et al.Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma[J].Blood,1995,86(2)∶685-691.
  • 6[5]Sawamura M,Murakami H,Tsuchiya J.Tumor necrosis factor-α and interleukin 4 in myeloma cell precursor differentiation[J].Leuk Lymphoma,1996,21(5)∶31-36.
  • 7Stasi R, Brunetti M, Parma A, et al. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer, 1998, 82:1860-1866.
  • 8Pelliniemi T T, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood, 1995, 85:765-771.
  • 9Ohtani K, Ninomiya H, Hasegawa Y, et al. Clinical significance of elevated soluble interleukin-6 receptor levels in sera of patients with plasma cell dyscrasias. Br J Haematol, 1995, 91:116-120.
  • 10李娟,罗绍凯,洪文德,黄俊琪.体外沙利度胺抑制骨髓瘤细胞生长及其机制的研究[J].中国实验血液学杂志,2002,10(1):70-72. 被引量:11

共引文献12

同被引文献19

  • 1陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价[J].癌症,2006,25(4):461-464. 被引量:45
  • 2Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells[ J]. Int J Hematol, 2003, 78(2) :106-113.
  • 3Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma[J]. Blood, 2000,95(8) :2630-2636.
  • 4Terpos E, Politou M, Viniou N, et al. Significance of macrophage inflammatory protein-1 alpha ( MIP-1alpha ) in multiple myeloma [ J]. Leuk Lymphoma, 2005,46 (12) : 1699-1707.
  • 5Moller C, Strombcrg T, Juremam M, et al. Expression and function of chemokine receptors in human multiple mycloma[ J]. Leuke, 2003,17( 1 ) :203-210.
  • 6Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor(bFGF) ,vascular endothelial growth factor(VEGF) and hepatocyte growth factor(HGF) in multiple myeloma[ J]. Eur J Haematol, 2001,66(2) :83-88.
  • 7KLEIN B,TARTE K,JOURDAN M,et al.Survival and proliferation factors of normal and malignant plasma cells[J].Int J Hematol,2003,78:106-113.
  • 8ATSUSHI O,DHARMINDER C,GERRARD T,et al.IL-6 treggers cell growth via the ras-dependent mitogen-activated protein kinase cascade[J].J Immunol,1997,159:2212-2221.
  • 9HSIAO Y W,LIAO K W,HUNG S W,et al.Tumer-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity[J].J Immunol,2004,172:1508-1514.
  • 10DANKBAR B,PADRO T,LEO R,et al.Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma[J].Blood,2000,95:2630-2636.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部